TELA - NASDAQ
TELA Bio, Inc.
$1.14
+0.44%TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
At a Glance
Live Snapshottela
Cash at End of Period
Last Annual Value
51.09M
3-Year CAGR
7%
5-Year CAGR
-7%
10-Year CAGR
16%
TELA Bio, Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
TELA Bio, Inc. NASDAQ:TELA | 51.09M | 2.8% | 3.1% | N/A | |
 Coeptis Therapeutics, Inc. NASDAQ:COEP | 5.67M | 56.9% | 21.1% | N/A | |
 Equillium, Inc. NASDAQ:EQ | 30.28M | 9.3% | -9.7% | N/A | |
 Spectral AI, Inc. NASDAQ:MDAI | 15.39M | 47.6% | -0.9% | N/A | |
 Outlook Therapeutics, Inc. NASDAQ:OTLK | 8083.09B | 6917.3% | 1310.5% | 350.4% | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | 48.94M | -20.2% | 2.6% | N/A | |
 Biodesix, Inc. NASDAQ:BDSX | 19.07M | -10.2% | -10.3% | N/A | |
 Pulmonx Corporation NASDAQ:LUNG | 70.01M | -5.8% | -14.0% | N/A | |
 Cytosorbents Corporation NASDAQ:CTSO | 9.76M | -14.5% | -28.9% | 6.4% | |
 Cue Biopharma, Inc. NASDAQ:CUE | 27.29M | -17.5% | -15.8% | 6.2% | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 7.80M | 19.3% | -22.3% | N/A |
TELA Bio, Inc. Fair Value Envelope
Related Guides
Continue your TELA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.